MX2019006189A - Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. - Google Patents
Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.Info
- Publication number
- MX2019006189A MX2019006189A MX2019006189A MX2019006189A MX2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- drug
- hormone receptor
- parathyroid hormone
- targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428492P | 2016-11-30 | 2016-11-30 | |
| US201762553313P | 2017-09-01 | 2017-09-01 | |
| PCT/US2017/064081 WO2018102616A1 (en) | 2016-11-30 | 2017-11-30 | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006189A true MX2019006189A (es) | 2019-11-18 |
Family
ID=62241919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006189A MX2019006189A (es) | 2016-11-30 | 2017-11-30 | Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20200317745A1 (OSRAM) |
| EP (1) | EP3548012A4 (OSRAM) |
| JP (2) | JP7649624B2 (OSRAM) |
| CN (1) | CN110114065A (OSRAM) |
| AU (1) | AU2017367699B2 (OSRAM) |
| BR (1) | BR112019011070A2 (OSRAM) |
| CA (1) | CA3045458A1 (OSRAM) |
| IL (1) | IL266977B2 (OSRAM) |
| MX (1) | MX2019006189A (OSRAM) |
| WO (1) | WO2018102616A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019011070A2 (pt) * | 2016-11-30 | 2019-10-01 | Purdue Research Foundation | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide |
| EP3790574A4 (en) | 2018-05-30 | 2022-07-13 | Purdue Research Foundation | TARGETING ANABOLIC DRUGS TO ACCELERATE FRACTURE REPAIR |
| CN110551201B (zh) * | 2019-08-26 | 2020-04-28 | 杭州彗搏科技有限公司 | 一种新型骨形成蛋白2来源的环肽、制备方法及其应用 |
| EP4027899A4 (en) * | 2019-09-12 | 2023-08-16 | Radius Health, Inc. | METHODS OF ENHANCING SPINE FUSION USING ABALOPARATIDE |
| CN112646042A (zh) * | 2019-10-10 | 2021-04-13 | 陕西麦科奥特科技有限公司 | 活性多肽化合物 |
| CN116848146A (zh) * | 2020-09-03 | 2023-10-03 | I·S·Y·陈 | 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体 |
| MX2023004796A (es) * | 2020-10-26 | 2023-07-18 | Purdue Research Foundation | Compuestos, composiciones y metodos de uso para tratar fracturas oseas. |
| US20230390363A1 (en) * | 2020-10-26 | 2023-12-07 | Purdue Research Foundation | Compounds, Compositions and Methods of Use to Treat Spinal Fusions |
| WO2022149066A1 (en) * | 2021-01-05 | 2022-07-14 | Radius Health, Inc. | Treatment of long bone fractures with abaloparatide |
| US20250295725A1 (en) * | 2022-01-14 | 2025-09-25 | Purdue Research Foundation | Bone targeted treatment in osteogenesis imperfecta |
| WO2024246840A1 (en) * | 2023-06-01 | 2024-12-05 | Radius Health, Inc. | Methods for identification and quantitation of abaloparatide and related peptide impurities |
| WO2025019691A1 (en) * | 2023-07-19 | 2025-01-23 | Zymeron Corporation | Drug conjugates for bone marrow protection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2098283A1 (en) * | 1990-12-21 | 1992-06-22 | Richard P. Bozzato | Oxidation resistant variants of parathyroid hormone |
| WO1995002610A1 (en) * | 1993-07-13 | 1995-01-26 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| AU757658B2 (en) * | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| JP2000327583A (ja) * | 1999-05-17 | 2000-11-28 | Medei Sci Puraningu:Kk | 骨指向性ホルモン誘導体 |
| WO2004062588A2 (en) * | 2003-01-06 | 2004-07-29 | University Of Utah | Water-soluble polymeric bone-targeting drug delivery system |
| PL2348114T3 (pl) * | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
| US7863238B2 (en) * | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
| US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| US7803770B2 (en) * | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| CA2664734C (en) * | 2006-10-03 | 2023-08-01 | Radius Health, Inc. | Method of drug delivery for bone anabolic protein |
| ES2675174T3 (es) * | 2007-04-09 | 2018-07-09 | The Board Of Trustees Of The University Of Arkansas | Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea |
| RS53302B (sr) * | 2007-05-11 | 2014-08-29 | Alexion Pharma Holding | Alkalna fosfataza koja je usmerena na kosti, pribor i postupci upotrebe |
| EP2303288A4 (en) * | 2008-05-22 | 2015-04-22 | Univ Ramot | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| SG194570A1 (en) * | 2011-04-22 | 2013-12-30 | Radius Health Inc | Method of drug delivery for pth, pthrp and related peptides |
| CN102824647B (zh) * | 2011-06-13 | 2014-07-23 | 香港中文大学 | 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法 |
| CA2883707A1 (en) * | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
| EP3016674A4 (en) * | 2013-06-23 | 2017-03-15 | Wisconsin Alumni Research Foundation | Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same |
| WO2016141250A1 (en) * | 2015-03-03 | 2016-09-09 | Radius Health, Inc. | USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK |
| US10279044B2 (en) * | 2015-05-29 | 2019-05-07 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
| CN106039316B (zh) * | 2016-05-03 | 2019-04-02 | 同济大学 | 一种基于多肽构建的成骨细胞靶向载体及其制备与应用 |
| BR112019011070A2 (pt) * | 2016-11-30 | 2019-10-01 | Purdue Research Foundation | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide |
| MX2023004796A (es) * | 2020-10-26 | 2023-07-18 | Purdue Research Foundation | Compuestos, composiciones y metodos de uso para tratar fracturas oseas. |
-
2017
- 2017-11-30 BR BR112019011070-4A patent/BR112019011070A2/pt active Search and Examination
- 2017-11-30 IL IL266977A patent/IL266977B2/en unknown
- 2017-11-30 JP JP2019529240A patent/JP7649624B2/ja active Active
- 2017-11-30 MX MX2019006189A patent/MX2019006189A/es unknown
- 2017-11-30 US US16/464,164 patent/US20200317745A1/en not_active Abandoned
- 2017-11-30 AU AU2017367699A patent/AU2017367699B2/en active Active
- 2017-11-30 EP EP17875427.1A patent/EP3548012A4/en active Pending
- 2017-11-30 CA CA3045458A patent/CA3045458A1/en active Pending
- 2017-11-30 WO PCT/US2017/064081 patent/WO2018102616A1/en not_active Ceased
- 2017-11-30 CN CN201780073942.4A patent/CN110114065A/zh active Pending
-
2020
- 2020-03-31 US US16/836,366 patent/US10960054B2/en active Active
-
2021
- 2021-02-24 US US17/184,400 patent/US20210283227A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193738A patent/JP2023029957A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200316174A1 (en) | 2020-10-08 |
| US20200317745A1 (en) | 2020-10-08 |
| AU2017367699A1 (en) | 2019-07-11 |
| JP2023029957A (ja) | 2023-03-07 |
| IL266977B2 (en) | 2024-01-01 |
| EP3548012A4 (en) | 2020-07-22 |
| JP7649624B2 (ja) | 2025-03-21 |
| AU2017367699A8 (en) | 2019-07-25 |
| JP2020500871A (ja) | 2020-01-16 |
| RU2019119701A3 (OSRAM) | 2021-02-16 |
| US20210283227A1 (en) | 2021-09-16 |
| EP3548012A1 (en) | 2019-10-09 |
| IL266977A (en) | 2019-07-31 |
| AU2017367699B2 (en) | 2023-12-07 |
| CA3045458A1 (en) | 2018-06-07 |
| WO2018102616A1 (en) | 2018-06-07 |
| BR112019011070A2 (pt) | 2019-10-01 |
| CN110114065A (zh) | 2019-08-09 |
| RU2019119701A (ru) | 2021-01-14 |
| US10960054B2 (en) | 2021-03-30 |
| IL266977B1 (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017367699A8 (en) | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation | |
| EP4421094A3 (en) | Targeted therapeutic agents and uses thereof | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| IN2015DN03219A (OSRAM) | ||
| SG11201810939PA (en) | Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| MX350378B (es) | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. | |
| WO2014052935A3 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| MX2018014279A (es) | Tratamiento terapeutico de cancer de mama con base en estado de c-maf. | |
| MX2020011333A (es) | Uso terapeutico de proteinas morfogeneticas oseas. | |
| MX2018004041A (es) | Tratamiento de trastornos de acidos biliares. | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| MX2019013857A (es) | Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. | |
| NZ721835A (en) | An osseointegrable device | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2017016418A (es) | Composiciones de liraglutida de acción prolongada. | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp | |
| BR112017002878A2 (pt) | distribuição coordenada de tratamento de copd | |
| BR112019024875A2 (pt) | Métodos para o tratamento da ileíte do reservatório crônica | |
| PH12016501733A1 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| EP3626712A3 (en) | Liver x receptor (lxr) modulators | |
| WO2020086479A9 (en) | Dosing | |
| SG11201808253YA (en) | Marker for predicting treatment response to anti-cancer agent in solid cancer patients | |
| MX380088B (es) | Uso terapéutico de una solución oftálmica acuosa estéril. | |
| PH12018502195A1 (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases |